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background:  The renin-angiotensin-aldosterone system (RAAS) is activated in heart failure (HF) as a compensatory mechanism. However, long-
term activation the RAAS eventually has an adverse effect. Although RAAS inhibitors are used as first-line drugs for HF, the plasma renin activity 
(PRA) is up-regulated by RAAS blockers via a negative feedback mechanism. The clinical implication of PRA under use of RAAS inhibitors is poorly 
understood in ADHF.
Methods:  Of 612 consecutive patients with ADHF emergently admitted to our hospital, we investigated the impact of PRA on the prognosis of ADHF 
in 293 patients who had already received RAAS inhibitors before admission. The patients were divided into 2 groups according to the median value 
of PRA (≥ or < 3.4 ng/ml/h).
results:  During a mean follow-up of 29.0 months, there were 124 all-cause death, including 68 cardiovascular death. Kaplan-Meier analysis 
showed that all-cause and cardiovascular death were significantly higher in High PRA group. In a multivariate analysis, including clinical and 
laboratory variables, High PRA group was the independent predictor than BNP for all cause death and cardiovascular death (HR=2.26; 95%CI 1.53-
3.35; P<0.0001 and HR=3.67; 95%CI 2.12-6.55; P<0.0001, respectively). Moreover, PRA predicted more strongly than BNP.
conclusions:  PRA was associated with increasing risk for adverse outcome for ADHF patients, even in those who are already receiving RAAS 
inhibitors, suggesting PRA would be useful biomarker in the treatment of ADHF.
 
